Click here for Food Allergy Trials.
Microbiome, Atopy and Prematurity (MAP) study
Principal Investigators: Drs. Sydney Leibel and Bob Geng
This is a study designed to determine the role of the microbiome in the development of allergic conditions in those with a history of prematurity. If your child is between 3-6 years old, has a history of prematurity (less than 36wks gestation) and has asthma, he/she may be eligible to participate. Those without a history of asthma may also qualify as a control group. Please contact Dr. Jessica Galant-Swafford at jgalantswafford@health.ucsd.edu for more information.
Preventing Asthma in High-Risk Kids (PARK) study
Principal Investigators: Drs. Sydney Leibel and Bob Geng
A study designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug. If your child is between 2-3 years old, has wheezing, and a family history of asthma or allergies, he/she may be eligible to participate. Please contact Diba Mortazavi, at dmortazavi@ucsd.edu for more information. https://clinicaltrials.gov/ct2/show/NCT02570984
IL-18 Binding Protein (Tadekinig) in Pediatric Patients with NLRC4 and XIAP1
Principal Investigator: Dr. Hal Hoffman
This is a study designed to determine if an investigational drug is safe and effective in patients 17 years old and under with NLRC4 and XIAP1 mutations.
Please contact Dr. Hal Hoffman at hhoffman@rchsd.org for more information.
https://clinicaltrials.gov/ct2/show/NCT03113760?cond=nlrc4&draw=2&rank=1
Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)
Principle Investigator: Dr. Seema Aceves
Database and sample collection study
Please contact Kira Chaiboonma at kchaiboonma@health.ucsd.edu for more information.
https://clinicaltrials.gov/ct2/show/NCT03980886
Somatization, Anxiety and Disordered Sleep in Pediatric Eosinophilic Esophagitis
Principle Investigator: Dr. Seema Aceves
To understand the symptoms and severity of anxiety, disordered sleep and somatization and how these parameters align with symptoms and quality of life in pediatric EoE.
Please contact Kira Chaiboonma at kchaiboonma@health.ucsd.edu for more information.
https://clinicaltrials.gov/ct2/show/NCT04309786
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE), Multicenter
Sponsor: Regeneron Pharmaceuticals
Principle Investigator: Dr. Seema Aceves
To evaluate the safety, tolerability and immunogenicity of dupilumab treatment for up to 52 weeks in adult and adolescent patients with EoE
To explore the relationship between dupilumab concentration and responses in adult and adolescent patients with EoE, using descriptive analyses
https://clinicaltrials.gov/ct2/show/NCT03633617
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA)
Principle Investigator: Dr. Seema Aceves
To find the best measures to define how well a person with eosinophilic disorder is doing.
Please contact Kira Chaiboonma at kchaiboonma@health.ucsd.edu for more information.